
Experts Offer Guidance on Use of DAAs for Difficult-To-Treat Hep C Patients
May 2012For several months, it has been one of the most pressing questions among clinicians who treat patients with hepatitis C: How well do the two FDA-approved direct-acting antivirals perform in the ...
read more